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Abstract
Several methyltransferases have been shown to catalyze the oxidative methylation of inorganic
arsenic (iAs) in mammalian species. However, the relative contributions of these enzymes to the
overall capacity of cells to methylate iAs have not been characterized. Arsenic (+3 oxidation state)
methyltransferase (AS3MT) that is expressed in rat and human hepatocytes catalyzes the conversion
of iAs, yielding methylated metabolites that contain arsenic in +3 or +5 oxidation states. This study
used short hairpin RNA (shRNA) to knock down AS3MT expression in human hepatocellular
carcinoma (HepG2) cells. In a stable clonal HepG2/A cell line, AS3MT mRNA and protein levels
were reduced by 83 and 88%, respectively. In comparison, the capacity to methylate iAs decreased
only by 70%. These data suggest that AS3MT is the major enzyme in this pathway, although an
AS3MT-independent process may contribute to iAs methylation in human hepatic cells.
Introduction
The metabolism of inorganic arsenic (iAs)1 in humans and in other mammalian species is a
complex process that yields various reactive and toxic intermediates and products. Reactions
involved in this process are enzymatically catalyzed (1). Enzymes have been identified that
catalyze the reduction of AsV-containing species (2–6) and the S-adenosylmethionine-
dependent methylation of AsIII-containing species (7,8). However, the significance of these
enzymes for in vivo metabolism of iAs and the linkage between steps in the metabolic pathway
for iAs remains unclear. Identification of a novel arsenic (+3 oxidation state) methyltransferase
(AS3MT) in rat liver (9) has allowed the study of iAs methylation at the molecular level. Results
of studies with recombinant rat AS3MT (rAS3MT) (10,11) showed that this enzyme catalyzes
the entire sequence of reactions that converts trivalent iAs, arsenite (iAsIII), to AsIII-or AsV-
containing methylarsenic (MAs), dimethylarsenic (DMAs), and trimethylarsenic (TMAs)
species that have been identified as intermediates or products in in vivo methylation of iAs in
rats (12,13). The presence of a synthetic reductant [e.g., tris-(2-carboxylethyl)phosphine] or
of one of the cellular reducing systems, thioredoxin/thioredoxin reductase/NADPH, lipoic
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acid/thioredoxin reductase/NADPH, or glutaredoxin/glutathione/glutathione reductase/
NADPH, is required for the activity of recombinant rAS3MT (11). Orthologues of rAS3MT
have been identified in genomes of other mammalian species, including human (14). An
orthologue of AS3MT (hAS3MT) [human arsenic (+3 oxidation state) methyltransferase] is
expressed in cultured primary human hepatocytes (15) that methylate iAsIII to MAs and DMAs.
MAs and DMAs, but not TMAs, have also been found as products of iAs methylation by
recombinant hAS3MT (16). The methylation patterns for iAs by human hepatocytes and by
recombinant hAS3MT are consistent with the results of epidemiological studies that found
MAsIII, MAsV, DMAsIII, and DMAsV, but not TMAs, in the urine of individuals chronically
exposed to iAs in drinking water (17–21). Notably, recent studies have linked hASMT
polymorphisms to specific methylation patterns for iAs in primary cultures of human
hepatocytes (15) and to specific urinary profiles of iAs metabolites found in residents of
arsenosis endemic areas of Mexico (22). Studies examining the characteristics of iAs
methylation by recombinant genetic variants of rAS3MT and hAS3MT are underway in several
laboratories, providing new data on the associations between AS3MT genotypes and specific
metabolic phenotypes (14,23).
Despite growing evidence that links the hAS3MT-catalyzed reactions to the metabolism of iAs
in humans, the relative contribution of this enzyme to the overall capacity to methylate iAs has
not been determined (24). In this study, we have silenced hAS3MT expression using RNA
interference (RNAi) in human hepatocellular carcinoma (HepG2) cells that constitutively
express hAS3MT. Short hairpin RNA (shRNA) vectors were used to deliver small interfering
RNA (siRNA) oligonucleotides complementary to hAS3MT transcript into HepG2 cells.
Quantitative analysis of hAS3MT mRNA and protein levels and of the pattern of iAs
metabolism in clonal HepG2/A cells that stably express hAS3MT-specific siRNA
oligonucleotides show that reduced hAS3MT expression is associated with a significant
reduction in the capacity to methylate iAs. This finding suggests that hAS3MT is the key
enzyme in the pathway for methylation of iAs in human hepatic cells.
Experimental Procedures
Caution
iAs has been classified as a human carcinogen (25) and should be handled accordingly.
Arsenicals
iAsIII, sodium salt (>98% pure), was purchased from Sigma (St. Louis, MO). Radiolabeled
carrier-free [73As]iAsIII was prepared by reduction of [73As]iAsV (Oak Ridge National
Laboratory, Oak Ridge, TN) with metabisulfite–thiosulfate reagent (26). The yield of [73As]
iAsIII in this reaction as determined by TLC (27) typically exceeded 95%.
Cells
HepG2 cells were obtained from the Tissue Culture Facility of the Lineberger Comprehensive
Cancer Center of the University of North Carolina at Chapel Hill. Cells were maintained in
minimum essential medium (MEM, Gibco BRL, Grand Island, NY) with 2 mM glutamine, 1
mM sodium-pyruvate, 0.1 mM nonessential amino acids, 1.5 g/L sodium bicarbonate, 10%
fetal bovine serum, penicillin (50 units/mL), and streptomycin (50 μg/mL) (all from Gibco) at
37 °C in a humidified incubator in a 5% CO2 atmosphere.
Design and Cloning of shRNA Cassettes
The BLOCK-iT RNAi Designer algorithm (Invitrogen, Carlsbad, CA) was used to analyze
hAS3MT mRNA (GenBank accession number, NM_020682) and to identify three target
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sequences for siRNA. Three shRNA constructs (shRNA/A, shRNA/B, and shRNA/C) that
contained the corresponding target sense and antisense sequences and the loop sequence
(Figure 1) were designed using the Small Interfering RNA Hairpin Oligonucleotide Sequence
Designer (Clontech Laboratories, Mountain View, CA). This design ensured that shRNA
constructs delivered into cells were efficiently transcribed and the transcripts folded properly
to form hairpin-like structures that were recognized by cellular enzymes. Selected shRNA
oligonucleotides were synthesized by Operon Biotechnologies (Huntsville, VA), purified by
PAGE, and cloned into pSIREN-RetroQ vectors, following the siRNA Hairpin
Oligonucleotide Sequence Designer protocol. Complete pSIREN-RetroQ-shRNA/A, /B, and /
C expression vectors were sequenced to verify insert orientation and nucleotide sequence.
Expression of shRNA Oligonucleotides in HepG2 Cells
The pSIREN-RetroQ-shRNA/A, /B, and /C expression vectors and an empty pSIREN-RetroQ
vector were used for transfection of the packaging AmphoPack-293 cells (Clontech). Here,
AmphoPack-293 cells were cultured in Dulbecco’s modified Eagle medium (DMEM; Gibco)
supplemented with 10% FBS, penicillin (50 units/mL), and streptomycin (50 μg/mL). Cells
were transfected using GeneJuice transfection reagent (Novagen, Darmstad, Germany) and
selected in DMEM medium containing puromycin (1 μg/mL, Sigma). Stable AmphoPack-293
cell lines producing retroviral particles containing pSIREN-RetroQ expression vectors were
established. Medium containing retroviral particles and polybrene (4 μg/mL, Sigma) was used
to infect HepG2 cells. Clonal HepG2 cell lines were then selected in MEM in the presence of
puromycin (2 μg/mL). Stable clonal HepG2 cell lines expressing the empty pSIREN-RetroQ
vector or vectors encoding for the shRNA/A, /B, and /C were established.
Analysis of hAS3MT mRNA
hAS3MT mRNA levels in parental and clonal HepG2 cell lines were analyzed by touch-down
PCR and quantified by real-time PCR as previously described (15,27). Briefly, 1 μg of DNase-
treated and purified total RNA was reverse transcribed. The following primers were used for
the touch-down PCR: hAS3MT/sense, 5′-CGTCTATACGAGCCTTGAA-3′; hAS3MT/
antisense, 5′-TTAGCAGCTTTTCTTTGTGC-3′. These primers amplify a 616 bp segment of
hAS3MT cDNA (nucleotide no. 555–1170) in which all three sequences targeted by shRNA
constructs are located. β-Actin mRNA was analyzed in parallel with hAS3MT mRNA, using
the following PCR primers: sense, 5′-TCATGAAGTGTGACGTGGACATCCGC-3′;
antisense, 5′-CTAGAAGCATTTGCGGTGGACGATG-3′. These primers amplify a 284 bp
segment of β-actin cDNA. Quantitative PCR analysis was carried out with 100 ng of total RNA,
using a computerized LightCycler Instrument (Roche Applied Science, Manheim, Germany).
The set of hAS3MT-specific primers designed for touch-down PCR was also used for
quantitative PCR. The PCR product was detected using LightCycler FastStart DNA
MasterPlus SYBR Green I (Roche Applied Science). A hAS3MT expression (pRSET/
hAS3MT) vector was used as a positive control and to generate a calibration curve for
quantification of hAS3MT mRNA (10,15,27).
Immunoblot Analysis
The hAS3MT protein levels in parental and clonal HepG2 cells were analyzed by immunoblot
using a rabbit polyclonal anti-hAS3MT antibody generously provided by Professor R. M.
Weinshilboum (Mayo Clinic College of Medicine, Rochester, MN). Cell lysates were prepared
in RIPA buffer as previously described (27). Aliquots of 30 μg of total protein were separated
by NuPAGE in a 10% Bis-Tris gel and 3-(N-morpholino)-propanesulfonic acid (MOPS) SDS
running buffer (Invitrogen) and electroblotted to polyvinylidene difluoride (PVDF) membrane.
After it was blocked with 5% nonfat milk for 1 h at room temperature, the membrane was
probed with a rabbit anti-hAS3MT antibody (1:2000) for 1 h at room temperature. β-Actin was
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analyzed in parallel with hAS3MT as a loading control, using a mouse monoclonal antibody
(Abcam, Cambridge, MA). Antibody-antigen complexes were visualized by enhanced
chemiluminescence detection (Amersham, Biosciences, Pittsburgh, PA) after incubation with
the corresponding HRP-conjugated antibody (Santa Cruz Biotechnology, Santa Cruz, CA) for
1 h at room temperature. The chemiluminescence signal was analyzed by a FluorChem Imaging
System (Alpha Innotech Corp., San Leandro, CA), using AlphaE-aseFCTM software (Alpha
Innotech). The β-actin signal was used to normalize hAS3MT protein contents in parental and
clonal HepG2 cell lines.
Analysis of iAs Metabolism
Metabolism of iAs was examined in parental and clonal HepG2 cells incubated with carrier-
free [73As]iAsIII. Radiolabeled metabolites in cells and culture media were analyzed by TLC
(28). Radioactivity associated with iAs, MAs, and DMAs was quantified with a computerized
Fuji FLA-5000 imaging system (Fujifilm, Stamford, CT).
Statistical Analysis
Results of quantitative PCR analysis were statistically evaluated using GraphPad Instat
software package (GraphPad Software Inc., San Diego, CA). One-way ANOVA followed by
Tukey’s multiple comparison test evaluated differences between experimental groups.
Differences at the p < 0.05 level were considered statistically significant.
Results and Discussion
Techniques involving the posttranscriptional silencing by RNAi have widely been used for
analyses of gene functions in mammalian cells. Initially, transfection was used for the delivery
of siRNA oligonucleotides complementary to target gene sequences. As compared with this
approach, a relatively new methodology using shRNA offers a significant advantage in
silencing longevity and delivery options. Retrovirus-delivered shRNA permits efficient
delivery and immediate selection of stable knockdown cell lines. Integrated shRNA is
transcribed in cells from a DNA template as a single-stranded RNA molecule. Complementary
regions spaced by a small loop (Figure 1) cause the transcript to fold in a “short hairpin”
conformation that resembles cellular microRNA. This molecule is a substrate for the
endogenous enzyme Dicer (29). The siRNA released by shRNA digestion enters into a nuclease
complex to form an RNA-induced silencing complex (RISC). RISC targets a complementary
endogenous gene transcript, cleaving mRNA or suppressing translation (30,31). Notably, an
shRNA construct has recently been used by Dhankher and associates (32) to silence expression
of arsenate reductase (ACR2) in Arabidopsis thaliana. ACR2 silencing resulted in a significant
decrease in ACR2 protein level, loss of the capacity to reduce arsenate, and hyperaccumulation
of arsenic in the shoots of the plant.
In this study, we tested three sequences in the open reading frame (ORF) of hAS3MT gene as
potential targets for siRNA. Blast analysis using the BLOCK-iT RNAi Designer database
(Invitrogen) confirmed that each selected sequence is unique and highly specific for
hAS3MT. Selected sequences are located 885–905, 919–939, and 973–993 bp in the ORF of
hAS3MT. shRNA constructs were designed containing siRNA oligonucleotides that target
each selected sequence (shRNA/A, shRNA/B, and shRNA/C). A retroviral expression pSIREN-
RetroQ vector delivered shRNA constructs to HepG2 cells and allowed selection of stable
genetically modified HepG2 cells. Those clonal cell lines expressing shRNA/A, /B, and /C were
designated as HepG2/A, HepG2/B, and HepG2/C, respectively. The clonal cell line expressing
empty pSIREN-RetroQ vector was designated as HepG2/Empty.
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Cell morphology, proliferation rates, hAS3MT expression, and capacity for iAs methylation
were compared in parental and clonal HepG2 cells. No significant differences in cell
morphology or in proliferation rates were found between parental and clonal cell lines during
12 weeks in culture (i.e., about 24 passages). Analysis of hAS3MT expression by conventional
(touch-down) RT-PCR found that HepG2/A cells expressed less hAS3MT mRNA than did
parental and other clonal cell lines (Figure 2a). Quantitative analysis by real-time PCR
confirmed that HepG2/A cells contained only 17% of hAS3MT mRNA found in parental
HepG2 cells (Figure 2b). Significantly less hAS3MT mRNA was detected in HepG2/B but not
in HepG2/C or HepG2/Empty cells, indicating that the capacity to suppress hAS3MT
expression varied markedly among the three shRNA constructs. Consistent with PCR data,
immunoblot analysis showed that HepG2/A and HepG2/B cells contained significantly less
hAS3MT protein that did HepG2, HepG2/Empty, or HepG2/C cells (Figure 3). The normalized
levels of hAS3MT protein in HepG2/A and HepG2/B cells were less than 12 and 30% of that
found in parental HepG2 cells, respectively. A statistically significant linear correlation (R =
0.997, p < 0.0001) between the hAS3MT mRNA level and the normalized hAS3MT protein
level was found for the five HepG2 cell lines examined (data not shown). To examine how the
suppression of hAS3MT expression affected capacity to methylate iAs, parental HepG2 and
clonal cell lines were incubated for 72 h in the presence of carrier-free [73As]iAsIII and
radiolabeled metabolites were analyzed in cell lysates and culture medium. Parental HepG2
cells methylated about 63% of iAs; MAs and DMAs that were found in both cell lysates and
culture medium accounted for 10 and 53% of total 73As, respectively (Figure 4). A similar
portion of iAs (58%) was methylated by HepG2/Empty and HepG2/C cells. For both cells
lines, MAs and DMAs accounted for about 8 and 50% of total 73As, respectively. In contrast,
HepG2/B cells methylated less than 44% and HepG2/A cells methylated less than 25% of iAs.
MAs accounted for 13% of total 73As in both cell lines; DMAs represented 30 and 11% of
total 73As in HepG2/B and HepG2/A, respectively. Thus, given the percentage of methylated
iAs, silencing of hAS3MT expression in HepG2/A resulted in about a 60% decrease of the
methylation capacity. However, on the basis of the number of methyl groups transferred to iAs
(one for MAs and two for DMAs), the capacity of HepG2/A cells to methylate iAs represents
only 30% of the original capacity found in HepG2 cells.
HepG2 cells have frequently been used to study metabolism of nutrients and xenobiotics in
human liver (33,34). The liver is also thought to play a key role in the metabolism of iAs.
Notably, HepG2 cells are relatively efficient methylators of iAs. The rates and patterns of iAs
methylation by HepG2 cells (35) resemble those described in cultured primary human
hepatocytes (15). In addition, like primary human hepatocytes, HepG2 cells express hAS3MT.
Thus, HepG2 cells are an appropriate cell culture model in which the enzymatic processes
underlying metabolism of iAs in human liver can be examined. Because nonproliferating
primary hepatocytes are not suitable for RNAi-mediated gene silencing and for selection of
stable clonal cell lines, we chose HepG2 cells to examine the significance of hAS3MT
expression in iAs methylation in human liver. Comparisons of hAS3MT mRNA and protein
levels and the methylation patterns for iAs in parental HepG2 and clonal cells show that the
capacity of these cells to methylate iAs was strongly dependent on hAS3MT expression. The
quantitative association between hAS3MT silencing by RNAi and reduced capacity of HepG2
cells to methylate iAs suggest that hAS3MT may be the predominant enzyme in the pathway
for iAs methylation in human liver. However, the disproportional decrease in hAS3MT mRNA
(by 83%), AS3MT protein (by 88%), and methylation capacity (by 70%) in HepG2/A cells
indicates that a minor AS3MT-independent mechanism may contribute to the hepatic
methylation of iAs.
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Sequences and predicted folding for three shRNA oligonucleotides designed to silence
hAS3MT expression in HepG2 cells: I, target sense sequence; II, target antisense sequence
(siRNA); and III, loop sequence.
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hAS3MT mRNA levels in parental and clonal HepG2 cells. (a) PCR products generated by
touch-down PCR from hAS3MT and β-actin cDNA. Negative control (NC) represents a PCR
reaction, in which cDNA was replaced with water. Positive control (PC) represents a PCR
reaction in which cDNA was replaced with pRSET/hAS3MT expression vector. (b) hAS3MT
mRNA levels quantified by real-time PCR. Mean and SD values for three independent
measurements are shown. *The mean value is significantly different (p < 0.001) from that in
parental HepG2 cells.
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hAS3MT protein levels in parental and clonal HepG2 cells. (a) Immunoblot images of
hAS3MT and β-actin. A representative image from one of three independent cultures is shown.
(b) hAS3MT protein levels normalized for β-actin contents. Mean and SD values for the three
independent cultures are shown. *The mean value is significantly different (p < 0.05) from that
in parental HepG2 cells.
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Methylation of iAsIII by parental and clonal HepG2 cells: Radiolabeled metabolites in cell
lysates and media after a 72 h exposure to carrier-free [73As]iAsIII. Amounts of iAs, MAs, and
DMAs are expressed as a percentage of total 73As. The mean value for three culture wells is
shown for each metabolite. Although not shown, SD values did not exceed 10% of the
corresponding mean value. *The mean value for a metabolite is significantly different (p <
0.05) from the corresponding value in parental HepG2 cells.
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